83 results about "Hederagenin" patented technology

The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin.

The invention relates to a hederagenin and a preparation method and purposes thereof. The compound is that the hederagenin is distilled from Nigella glandulifera freyn by degreasing, leaching and macroporous resin absorption, a structure of the hederagenin is confirmed by using physico-chemical constants, spectra database and single crystal method of X-ray diffractometry, the distilled hederagenin is proved in vitro to have the effect of tyrosine protein phosphatase PTP1B retardant and purposes as anti-diabetes drugs and health care products, meanwhile, the hederagenin is also applicable to be combination of drugs made from the compound or derivatives of the compound.

The present invention is a method for preparing triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester and derivatives thereof from oleanic acid, ursolic acid, betulinic acid, sumaresinolic acid or hederagenin.

The invention relates to the field of organic synthesis and medicinal chemistry and specifically relates to an alpha-hederagenin derivative with a structure as shown in a general formula I. The invention discloses a preparation method for the alpha-hederagenin derivative, drug compounds containing the alpha-hederagenin derivative and application thereof in tumor drug-resisting reversion.

The invention discloses an fructus akebiae extract, which is prepared by a method of: taking an fructus akebiae medicinal material as a raw material, performing degreasing treatment first, then orderly performing ethanol extraction, ethyl acetate treatment and water saturated normal butanol extraction to obtain total saponin of fructus akebiae, and performing acid-containing ethanol degradation and purification treatment on the obtained total saponin to obtain the fructus akebiae extract, wherein the weight percentage of hederagenin in the fructus akebiae extract is not lower than 60 percent. The invention also discloses the method for preparing the fructus akebiae extract, a preparation and application thereof. The fructus akebiae extract has the advantages of less impurities, high content of active components, and scientific and reasonable steps; the preparation thereof is safe and effective and has reliable quality; and the fructus akebiae extract and the preparation thereof have good antidepression effect.

The invention belongs to the technical field of medicines, and in particular relates to hederagenin A-cyclopyrazine derivatives with novel structures and a preparation method of the hederagenin A-cyclopyrazine derivatives. The hederagenin A-cyclopyrazine derivatives with the novel structures have the structures as shown in the general formula I. The compounds disclosed by the invention have the same in-vivo drug resistance reversal activity as in vitro and can be directly administered in vivo. The invention further discloses a preparation method of the derivatives and the application of the derivatives to preparation of tumor drug resistance reversal agents directly used in vivo.

The invention provides a method for preparing sapogenin through chenopodium quinoa willdL seed coat and a separation and quantification method of the sapogenin, and belongs to the technical field of biological product processing. The method for preparing the sapogenin through the chenopodium quinoa willdL seed coat comprises the following steps that firstly, the chenopodium quinoa willdL seed coat, complex enzyme and deionized water are mixed and enzymolyzed to obtain enzymatic hydrolysate; then the enzymatic hydrolysate and ethyl alcohol are mixed, chenopodium quinoa willdL saponin in the enzymatic hydrolysate is extracted through ultrasonic waves, solid-liquid separation is conducted, and a chenopodium quinoa willdL saponin extracting solution is obtained; then the chenopodium quinoa willdL saponin extracting solution and hydrochloric acid are mixed and subjected to acidolysis to obtain acidolysis liquid; and finally, the acidolysis liquid is extracted through petroleum ether to obtain extract liquor, and a solvent in the extract liquor is removed through evaporation, and the sapogenin is obtained. According to the method, the chenopodium quinoa willdL seed coat serves as a raw material to prepare the sapogenin, the natural sapogenin raw material can be provided for a professional pharmaceutical factory, the comprehensive utilization rate and the economic added value of chenopodium quinoa willdL can further be increased, and reuse and sustainable development of resources are facilitated. The invention further provides a method for simultaneous separation and quantification of oleanolic acid and hederagenin in the chenopodium quinoa willdL seed coat through UPLC-MS.

The invention discloses a method for determining contents of effective components in Clematis chinensis Osbeck, which comprises the following steps of (1) preparing a reference solution; (2) preparing a test sample solution; and (3) precisely extracting the reference solution and the test sample solution respectively, injecting into a liquid chromatograph, and determining by an evaporative light-scattering detector to obtain the contents of effective components including oleanolic acid and hederagenin, wherein the chromatographic filler is selected from octadecylsilane chemically bonded silica, the mobile phase is selected from methanol-water-acetic acid-triethylamine with a volumetric ratio of (80-95):(5-20):(0.01-0.1):(0.01-0.1), and the theoretical plate number, calculated by oleanolic acid, is not less than 2,000. The method has simple operation and can accurately determine the contents of oleanolic acid and hederagenin in Clematis chinensis Osbeck.

The invention discloses a new application of total aglycone of himalayan teasel roots and single-component hederagenin in medicaments preparing Alpha-glucosidase inhibitor; the medicaments preparing the Alpha-glucosidase inhibitor can be the total aglycone of himalayan teasel roots, the single-component hederagenin, or a compound containing the total aglycone of himalayan teasel roots and the single-component hederagenin, which all can be prepared into tablets, capsules, granules, injections and suspensions.

The invention relates to hederagenin-based facial milk cleanser. Each part of facial milk cleanser comprises the following components by percentage: 5.0% to 8.0% of glycerol, 4.0% to 6.0% of propylene glycol, 0.1% to 0.2% of oleyl alcohol, 1.5% to 2.0% of polyoxyethylene sorbitan mono-laurate, 0.5% to 1.2% of polyoxyethylene lauryl alcohol, 1.0% to 2.0% of hederagenin, 10.0% to 12.0% of ethanol, 0.1% to 0.5% of essence and distilled water in balancing amount. The application method of the hederagenin-based facial milk cleanser comprises the following steps: wetting the face by water; holding a proper amount of the hederagenin-based facial milk cleanser in the palm; adding a small amount of water to the hederagenin-based facial milk cleanser, and lathering; lightly circling the hederagenin-based facial milk cleanser over the face for 1 to 2 minutes; and cleansing with clean water. The hederagenin-based facial milk cleanser targeting on greasy skin is capable of generating fine, smooth and abundant lather and thoroughly cleansing the pores, so that the skin can be clean, smooth and grease-free after the administration; and the hederagenin-based facial milk cleanser is also capable of improving the moisture barrier effect of the skin and keeping the balance of water and grease.

The invention discloses a method for extracting, separating and purifying chemical components of walnut green seedcases and application of the chemical components. According to the method, 13 compounds are separated from the walnut green seedcases and respectively identified as 3,5-dimethoxy-4-hydroxy-benzoic acid-7-O-beta-D-glucoside (1), myricananin F (2), beta-sitosterol (3), oleanolic acid (4), walnut ketone (5), asiatic acid (6), hederagenin (7), beta-carotene (8), (4R)-4,8-dihydroxy-alpha-tetralone-4-O-beta-D-glucopyranoside (9), 3beta,23-dihydroxy-12-olefin-28-ursolic acid (10), ursolicacid (11), syringic acid (12) and Juglanoside B (13). After screening of anti-tumor activity in vitro, it is found that some compounds have certain growth inhibitory activity against cancer cells andcan be further used for preparing anticancer drugs.

The invention relates to application of hederagenin-3-O-arabinopyranoside (hederagenin-3-O-arabinopyranoside). The Hederagenin-3-O-arabinopyranoside is obtained by utilizing a chemical extraction separation method. The chemical compound structure of the hederagenin-3-O-arabinopyranoside is identified by utilizing physical constants and spectroscopy methods to carry out an antineoplastic pharmacological testing for the hederagenin-3-O-arabinopyranoside, a result shows that the hederagenin-3-O-arabinopyranoside has good effect on antineoplastic aspects ,especially has good effects on restraining human breast cancer cells, sarcoma cells, gastric carcinoma cells, hepatoma carcinoma cells and prostate cancer cells. The hederagenin-3-O-arabinopyranoside can be used for preparing medicines for curing breast cancer, solid tumor, gastric cancer, liver cancer and prostate cancer.

The invention discloses the application of hederagenin or the medical salt thereof in the preparation of medicine for resisting senile dementia, cranial nerve damage and aging. According to the invention, the hederagenin or the medical salt thereof is used for treating the diseases, the curative effect is excellent, the side effect is small, the security is high, and a novel selection is provided for treating senile cerebral diseases.

The invention provides a method for preparing hederagenin from soapberries. The method comprises the steps that soapberry total saponin is extracted through an ethanol-water mixture solvent, hydrolysis is carried out and crystallization process purification is carried out to obtain the hederagenin. The method for preparing hederagenin is high in yield, simple in operation, mild in condition, low in cost, free of pollution and environmentally friendly. By means of the method for preparing hederagenin, high-purity hederagenin can be obtained, the production cost is lower compared with the prior art, the yield is greatly improved, the application prospect is wide, and the requirements of rapidly-developed medical industry can be met.

The invention provides a triterpenoid saponin compound extracted from clematis tangutica. The molecular formula of the triterpenoid saponin compound is C59H96O27. The chemical structure of the compound is determined as 3beta-O-[3-O-alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyranoside]-21alpha-hydroxy-Chinese ivy-28-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranose-(1->6)-beta-D-glucopyranose(21alpha-dydroxy-3beta-O-[3-O-alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyran osyl]-hederagenin-28-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside) by adopting spectrum technologies such as a high-resolution mass spectrum, a two-dimensional nuclear magnetic resonance spectrum and the like and a chemical method. As proved by an in-vitro anti-myocardial ischemia active result, the compound plays a remarkable role in protecting myocardial injury induced by an anoxic/reoxygenation model. The invention provides a lead compound for treating myocardial ischemia diseases, and the triterpenoid saponin compound can become a new cardiovascular medicament.

Disclosed are compositions enriched with thymohydroquinone, further comprising of thymoquinone, hederagenin and/or α-hederin formulated by blending the active molecules isolated from the seeds of Nigella sativa. Also disclosed are novel processes for the isolation of bioactive components thymohydroquinone, thymoquinone from the seeds of Nigella sativa. A process for the isolation α-hederin and hederagenin from the spent material of Nigella sativa is also disclosed herein.

The invention discloses application of hederagenin and glucoside thereof in preparing anti-virus medicines, and provides application of No.1-15 hederagenin or saponin in preparing anti-virus medicines. Proofed by experiment results, the No.1-15 hederagenin or saponin has obvious protection function on RSV (respiratory syncytial virus), HSV-I (herpes virus-I) and CVB3 (coxsackie B3) virus-infectedmice; the death protection rate (%) of the No.1-15 hederagenin or saponin on the RSV, HSV-I and CVB3 virus-infected mice is 35% or above; the life elongation rate (%) of the No.1-15 hederagenin or saponin on the RSV, HSV-I and CVB3 virus-infected mice is 50% or above, so that the No.1-15 hederagenin or saponin can be developed into the antivirus medicines.

The invention provides application of a hederagenin compound serving as a medicament for treating liver cancer and a preparation of the hederagenin compound. The hederagenin compound of a liver cancer treatment medicament is successfully prepared from hederagenin and derivatives thereof by separating purification hydrolysis and chemical synthesis methods from plants. The hederagenin compound provided by the invention is subjected to anti-hepatoma activity screening, and screening results discover that the hederagenin compound has remarkable anti-hepatoma activity, and can be used for treating patients with liver cancer after being prepared into medicaments for treating liver cancer. Reports on the hederagenin and a series of derivatives with the compound frame serving as medicaments for treating liver cancer are not found until now by means of searching.